Jade Biosciences (JBIO) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jade Biosciences is the larger company by market cap ($899.9 million vs $870.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JBIO | ODTX |
|---|---|---|
| Share price | $14.15 | $18.12 |
| Market cap | $899.90M | $870.82M |
| 1-day change | +2.76% | +0.22% |
| YTD return | -10.76% | — |
| 1-year return | +52.32% | — |
| 5-year return | -97.22% | — |
| EPS (TTM) | $-1.92 | $-7.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $29.05 |
| 52-week low | $8.36 | $15.10 |
| Distance from 52-week high | -49.46% | -37.62% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +254.28% | +97.30% |
| Average volume | 888.66K | 270.92K |
| Shares outstanding | 63.60M | 48.06M |
| Employees | 55 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
JBIO vs ODTX FAQ
Which is bigger, Jade Biosciences or Odyssey Therapeutics?
Jade Biosciences (JBIO) is larger, with a market capitalization of $899.90M compared with $870.82M for Odyssey Therapeutics (ODTX).
Are Jade Biosciences and Odyssey Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Jade Biosciences and Biotechnology: Biological Products (No Diagnostic Substances) for Odyssey Therapeutics.